U.S. Luxury Stock News

Fortrea Holdings (FTRE) remains unprofitable, with losses accelerating at a 52.8% annual rate over the past five years. Looking ahead, analysts expect the company to stay in the red for at least three more years, while revenue growth is projected at just 2.4% per year, lagging the US market’s 10.5%. Despite trading at a Price-to-Sales Ratio of 0.4x, which is well below industry and peer averages, the current share price of $11.95 sits significantly under the estimated fair value of $18.73...

Atlanta Braves Holdings (BATR.K) remains unprofitable but has managed to reduce its losses by 6.9% per year over the past five years. With earnings projected to grow at 61.05% annually and the turning point to profitability anticipated within three years, ongoing loss reduction and expected profit growth are now the key points for investors keeping an eye on the company's earnings trajectory. See our full analysis for Atlanta Braves Holdings. Next up, we will stack these headline results...

Recursion Pharmaceuticals (RXRX) remains firmly in the red, with losses increasing at an average rate of 35.2% per year over the past five years and no improvement in net profit margin. Despite this, revenue is forecast to accelerate at an impressive 30.1% per year, outpacing the broader US market’s projected 10.5% annual growth. Investors are weighing strong top-line growth expectations against a persistent track record of operating losses, a premium price-to-sales ratio of 33.6x, and a...

Lemonade (LMND) is forecast to grow revenue at 27.1% per year, outpacing the US market average of 10.5% per year. Still, the company remains unprofitable, with losses increasing at a rate of 5.7% per year over the past five years and profitability not expected within the next three years. While investors may be drawn to the rapid growth potential, ongoing losses and lack of near-term profitability are likely to weigh on sentiment. See our full analysis for Lemonade. Next up, we will see how...

Montrose Environmental Group (MEG) is forecasting revenue growth of 5.5% per year, trailing the wider US market’s expected 10.5% pace. The company remains in the red, but it has trimmed annual losses by an average of 11.1% over the past five years. While profitability remains elusive, investors are weighing the steady narrowing of losses against slower sales expansion and a premium Price-To-Sales Ratio. See our full analysis for Montrose Environmental Group. Now, let’s see how these latest...

Accel Entertainment (ACEL) reported a net profit margin of 2.8%, down from last year’s 4.1%. Despite achieving an impressive annualized earnings growth rate of 28.9% over the last five years, earnings turned negative in the most recent year, halting positive profit momentum. With revenue projected to grow at 3.8% per year and a price-to-earnings ratio of 24.3x, which is above the US Hospitality industry average, the numbers paint a more cautious outlook, especially given the stock trades...

California Resources (CRC) posted eye-catching results this quarter, with net profit margins jumping to 18.3%, up from 7.2% a year ago. Earnings rebounded 305.5% year-over-year, a major turnaround from the company’s five-year average decline of -25.6% annually. The share price sits at $46.27, well below an analyst fair value estimate of $114.76. This signals that investors are weighing strong profitability against looming concerns over slower revenue growth and projected earnings...

Curious whether Royalty Pharma is trading at a bargain, or if its recent performance signals something more? You are not alone. Valuation-focused investors have been eyeing this stock closely. After a strong run, Royalty Pharma’s shares are up 10.2% in the last week and 11.9% this month, racking up an impressive 56.7% gain year-to-date. Recent headlines have highlighted Royalty Pharma's aggressive moves in acquiring new royalty interests and expanding its biopharma portfolio. Both of these...

ACM Research (ACMR) is on track for robust growth, with revenue forecast to climb 15% per year, well ahead of the broader US market’s 10.5% annual growth. EPS is set to expand by 14.3% annually, net profit margins have increased to 13.8% from 12.3% last year, and earnings have averaged a 37% annual increase over the past five years. Investors may take notice as strong margin improvement and premium revenue growth continue to support a positive outlook, even as recent share price stability...

Niagen Bioscience (NAGE) posted annual revenue growth of 17.4%, beating the US market’s 10.5% pace. The bottom line also showed a significant turnaround, as the company turned profitable in the last year with a notable improvement in net profit margin. Earnings are now expected to grow at a rapid 41.2% per year over the next three years, compared to the broader market’s 16% growth estimate. Shares currently trade at $6.88, which is well below management’s internal fair value mark of $18.44...

Inogen (INGN) continues to face pressure on the bottom line, with losses rising at an annualized rate of 31.9% over the past five years and expectations set for ongoing unprofitability over the next three years. At the same time, revenue growth is forecast at just 6.2% per year, trailing the broader US market’s projected 10.5% pace. The company has not demonstrated any improvement in net profit margin during the last year. While the earnings outlook remains challenging, valuation metrics...

Hyster-Yale (HY) reported earnings shaped by a mix of standout historical growth and recent setbacks. Over the past five years, earnings have climbed at a 42.2% annual rate, but the latest period saw earnings dip due to a one-off $38.5 million loss. Net profit margins slipped to 0.6% from 4.1% last year, highlighting the recent profitability pressure. With revenue expected to grow at 2% per year and earnings forecast to accelerate at 31.7% annually, well above the U.S. market average,...

Tile Shop Holdings (TTSH) delivered another difficult quarter, with ongoing unprofitability and no progress in net profit margin over the past year. Losses have deepened at an average annual rate of 16.6% over the last five years, and shares currently trade at $6.37, well above an estimated fair value of $1.44. With no expectation of revenue or earnings growth on the horizon and a Price-To-Sales Ratio of 0.8x that looks stretched compared to sector benchmarks, investors have little near-term...

Sleep Number (SNBR) continues to face headwinds, reporting another year of rising losses, which have increased at an annual rate of 67.7% over the past five years. Despite a persistently negative net profit margin, the outlook has brightened with forecasts calling for annual earnings growth of 97.54% and a return to profitability within the next three years. This rate would outpace the broader market. Revenue is expected to grow at 3.6% per year, trailing the US average of 10.5%. However,...

Trinity Capital (TRIN) delivered high quality earnings this period, with net profit margins rising to 54.4%, up from 41.8% a year ago. The company has been profitable over the past five years and recently reported an impressive 73.7% annual earnings growth rate, well ahead of its five-year average of 19.5%. While profitability trends remain strong, analysts are forecasting much slower growth ahead, with annual earnings expected to tick up just 0.2% and revenue to grow at 3.8%. This suggests a...

Par Pacific Holdings (PARR) remains unprofitable, but has managed to cut its losses at an impressive clip of 41.2% per year over the past five years. Investors are eyeing a projected 0.4% annual revenue decline over the next three years and continue to grapple with both negative net profit margins and ongoing poor earnings quality, as the company shows no signs of recent profitability to benchmark against previous years. With margins under pressure, the latest results set the stage for a key...

Berry (BRY) has become profitable over the past five years, reporting an average earnings growth of 41.6% per year. Looking ahead, earnings are expected to surge another 159.2% annually, but revenue is forecast to decline at an average pace of -1.1% per year for the next three years. The company also recorded a one-off loss of $3.9 million in the most recent financial year, tempering the near-term earnings outlook. Investors will be weighing this mix of rapid projected earnings growth and...

Braemar Hotels & Resorts (BHR) remains unprofitable, with no improvement in its net profit margin over the last year. Over a five-year stretch, however, the company has steadily narrowed its losses at a rate of 7.3% per year. Revenue is forecast to grow at just 0.9% annually, compared to the broader US market’s projected 10.5% growth. In this operational context, BHR’s price-to-sales ratio of 0.2x stands out as especially low relative to both the industry and peers. The share price of $2.58...

Owens Corning (OC) is forecasting annual earnings growth of 20.4%, outpacing the broader US market’s expected 16% per year, but revenue is set to rise by just 1.5% per year compared to the market’s 10.5%. Net profit margin dropped to 6% from 10.8% last year, with the most recent numbers impacted by a one-off $675 million loss. Investors are watching closely as the company now trades at a P/E of 13.2x, well below both the US Building industry average and its peers, and its current share price...

XPEL (XPEL) posted revenue growth forecasts of 14% per year, comfortably beating the broader US auto components sector's 10.5% growth outlook. Earnings are predicted to accelerate even faster, with EPS expected to expand 30.7% per year, well ahead of the market's 16% annual average. Meanwhile, the current net profit margin edged down to 10.8% from last year's 11.6%. The combination of robust forecasted growth, a share price trading below estimated fair value at $35.31 per share, and...

Thinking of investing in BancFirst and wondering if the stock is truly undervalued, or if there is more to the story? You are not alone. Many savvy investors are taking a closer look at its numbers. BancFirst shares have been on a wild ride, rising 1.1% in the last week, despite dropping 13.0% over the past month and showing a year-to-date decline of 4.7%. However, if you zoom out, they are still up 130.4% over the past five years. Much of this recent volatility is linked to news around...

Ovintiv (OVV) has achieved an average annual earnings growth of 49.2% over the past five years. However, the latest 12 months saw net profit margin shrink to 6.6% from 18.8% in the previous year. Results for the period include a notable one-off loss of $1.2 billion, which weighed on reported earnings. Looking ahead, revenue is forecast to rise 2.8% per year, trailing the broader US market's expected 10.5% annual growth. Meanwhile, earnings are projected to climb 39.8% per year, outpacing the...

Taboola (TBLA) has turned profitable for the first time, with its net profit margin showing clear improvement over the past year. The company’s earnings are forecast to grow at an impressive 32.4% per year, more than double the US market’s average, while revenue is expected to grow at 6.9% annually, trailing the broader market’s 10.5%. Shares recently traded at $3.71, which is well below an estimated fair value of $10.05. The current Price-To-Earnings Ratio stands at a hefty 80.9x, indicating...

Avadel Pharmaceuticals (AVDL) continues to operate at a loss, with losses having grown at an average annual rate of 12.4% over the past five years and a net profit margin that remains unimproved year over year. Despite its current lack of profitability, Avadel’s revenue is forecast to climb 15.6% annually, which is ahead of the broader US market’s 10.5%. Earnings are projected to surge by 40.12% each year. The company is anticipated to reach profitability within three years, and with its...